Jamie Han, F. Chung, Q. Nguyen, F. V. Mody, C. Jackevicius
Despite evidence that supports the use of sacubitril/valsartan – the first angiotensin II receptor blocker–neprilysin inhibitor – for mortality reduction in patients with heart failure (HF), it remains underprescribed. The objective of this study was to evaluate eligibility for initiation of sacubitril/valsartan treatment in patients with HF within the largest Veterans Administration healthcare system in the United States.
{"title":"Evaluation of Patients with Heart Failure to Determine Eligibility for Treatment with Sacubitril/Valsartan: Insights from a Veterans Administration Healthcare System","authors":"Jamie Han, F. Chung, Q. Nguyen, F. V. Mody, C. Jackevicius","doi":"10.1002/phar.2328","DOIUrl":"https://doi.org/10.1002/phar.2328","url":null,"abstract":"Despite evidence that supports the use of sacubitril/valsartan – the first angiotensin II receptor blocker–neprilysin inhibitor – for mortality reduction in patients with heart failure (HF), it remains underprescribed. The objective of this study was to evaluate eligibility for initiation of sacubitril/valsartan treatment in patients with HF within the largest Veterans Administration healthcare system in the United States.","PeriodicalId":19812,"journal":{"name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77224799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
W. Eggleston, R. Stoppacher, Kyle Suen, J. Marraffa, Lewis S. Nelson
{"title":"Drs. Eggleston et al. Reply to Drs. Grundmann et al","authors":"W. Eggleston, R. Stoppacher, Kyle Suen, J. Marraffa, Lewis S. Nelson","doi":"10.1002/phar.2337","DOIUrl":"https://doi.org/10.1002/phar.2337","url":null,"abstract":"","PeriodicalId":19812,"journal":{"name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84057018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nicole E. Cieri‐Hutcherson, T. Hutcherson, Erin E. Conway‐Habes, Brianna N. Burns, Nathan A. White
l‐glutamine was approved by the U.S. Food and Drug Administration (FDA) for sickle cell disease (SCD) in 2017. A vaso‐occlusive crisis (VOC) occurs in persons with SCD and is associated with acute pain episodes. This systematic review summarizes the evidence for l‐glutamine in the prevention of VOC and associated pain in patients with SCD. Medline, Embase, and International Pharmaceutical Abstracts were searched for records reporting on l‐glutamine use in persons with SCD. Eligibility criteria identified primary reports of investigations conducted in humans who were administered l‐glutamine, reported on outcomes related to VOC or associated pain, published in English, and were available as full text. All relevant efficacy, safety, participant demographic data, and study method characteristics were extracted and documented. Risk‐of‐bias assessments were conducted using the Risk of Bias in Non‐Randomized Studies‐of Interventions (ROBINS‐I) tool and the revised Cochrane risk‐of‐bias tool for randomized studies. Three studies assessing the effect of exogenous l‐glutamine administration in patients with SCD met eligibility criteria: one prospective nonrandomized controlled study and two prospective randomized controlled trials. Rate of VOC and related hospitalizations were reduced in patients receiving l‐glutamine, although some conflicting results were noted between studies. l‐glutamine was generally well tolerated. Limitations of one or more of the eligible studies included small sample size, nonblinding, and study groups that differed at baseline. l‐glutamine has limited high‐quality evidence supporting its use. Although l‐glutamine is FDA approved for the prevention of frequent episodes of VOC pain, only one randomized controlled trial has strong evidence to support this indication. Based on the results of a systematic review, l‐glutamine may be considered for patients unable to receive hydroxyurea or in addition to hydroxyurea for reduction in VOC and associated pain.
{"title":"Systematic Review of l‐glutamine for Prevention of Vaso‐occlusive Pain Crisis in Patients with Sickle Cell Disease","authors":"Nicole E. Cieri‐Hutcherson, T. Hutcherson, Erin E. Conway‐Habes, Brianna N. Burns, Nathan A. White","doi":"10.1002/phar.2329","DOIUrl":"https://doi.org/10.1002/phar.2329","url":null,"abstract":"l‐glutamine was approved by the U.S. Food and Drug Administration (FDA) for sickle cell disease (SCD) in 2017. A vaso‐occlusive crisis (VOC) occurs in persons with SCD and is associated with acute pain episodes. This systematic review summarizes the evidence for l‐glutamine in the prevention of VOC and associated pain in patients with SCD. Medline, Embase, and International Pharmaceutical Abstracts were searched for records reporting on l‐glutamine use in persons with SCD. Eligibility criteria identified primary reports of investigations conducted in humans who were administered l‐glutamine, reported on outcomes related to VOC or associated pain, published in English, and were available as full text. All relevant efficacy, safety, participant demographic data, and study method characteristics were extracted and documented. Risk‐of‐bias assessments were conducted using the Risk of Bias in Non‐Randomized Studies‐of Interventions (ROBINS‐I) tool and the revised Cochrane risk‐of‐bias tool for randomized studies. Three studies assessing the effect of exogenous l‐glutamine administration in patients with SCD met eligibility criteria: one prospective nonrandomized controlled study and two prospective randomized controlled trials. Rate of VOC and related hospitalizations were reduced in patients receiving l‐glutamine, although some conflicting results were noted between studies. l‐glutamine was generally well tolerated. Limitations of one or more of the eligible studies included small sample size, nonblinding, and study groups that differed at baseline. l‐glutamine has limited high‐quality evidence supporting its use. Although l‐glutamine is FDA approved for the prevention of frequent episodes of VOC pain, only one randomized controlled trial has strong evidence to support this indication. Based on the results of a systematic review, l‐glutamine may be considered for patients unable to receive hydroxyurea or in addition to hydroxyurea for reduction in VOC and associated pain.","PeriodicalId":19812,"journal":{"name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84724008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
O. Grundmann, P. Brown, E. Boyer, Marc T Swogger, Z. Walsh, W. Prozialeck, Andrew C. Kruegel, Charles A. Veltri, S. Dudley
Emergency Medicine, Harvard Medical School, Brigham and Women’s Hospital, Boston, Massachusetts; Department of Psychiatry, University of Rochester Medical Center, Rochester, New York; Department of Psychology, University of British Columbia, Kelowna, British Columbia; Department of Pharmacology, College of Graduate Studies, Midwestern University, Downers Grove, Illinois; Department of Chemistry, Columbia University, New York, New York; College of Pharmacy-Glendale, Midwestern University, Glendale, Arizona; Arizona Poison and Drug information Center, Tucson, Arizona
{"title":"Critique of “Kratom Use and Toxicities in the United States”","authors":"O. Grundmann, P. Brown, E. Boyer, Marc T Swogger, Z. Walsh, W. Prozialeck, Andrew C. Kruegel, Charles A. Veltri, S. Dudley","doi":"10.1002/phar.2336","DOIUrl":"https://doi.org/10.1002/phar.2336","url":null,"abstract":"Emergency Medicine, Harvard Medical School, Brigham and Women’s Hospital, Boston, Massachusetts; Department of Psychiatry, University of Rochester Medical Center, Rochester, New York; Department of Psychology, University of British Columbia, Kelowna, British Columbia; Department of Pharmacology, College of Graduate Studies, Midwestern University, Downers Grove, Illinois; Department of Chemistry, Columbia University, New York, New York; College of Pharmacy-Glendale, Midwestern University, Glendale, Arizona; Arizona Poison and Drug information Center, Tucson, Arizona","PeriodicalId":19812,"journal":{"name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88511670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Muñoz, C. Delcher, G. D. Dal Pan, C. Kortepeter, E. Wu, Y. Wei, Hong Xiao, A. Winterstein
Consumers and healthcare professionals can voluntarily report adverse experiences associated with drug products to the United States Food and Drug Administration's (FDA) Adverse Event Reporting System (FAERS). Consumers and healthcare professionals used the same general voluntary reporting form (GVR) until mid‐2013, when a consumer voluntary reporting form (ConVR), written in plain language, was implemented. The objective of this study was to examine the effect of the ConVR on the quality and quantity of consumer reports submitted directly to FAERS.
{"title":"Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration","authors":"M. Muñoz, C. Delcher, G. D. Dal Pan, C. Kortepeter, E. Wu, Y. Wei, Hong Xiao, A. Winterstein","doi":"10.1002/phar.2325","DOIUrl":"https://doi.org/10.1002/phar.2325","url":null,"abstract":"Consumers and healthcare professionals can voluntarily report adverse experiences associated with drug products to the United States Food and Drug Administration's (FDA) Adverse Event Reporting System (FAERS). Consumers and healthcare professionals used the same general voluntary reporting form (GVR) until mid‐2013, when a consumer voluntary reporting form (ConVR), written in plain language, was implemented. The objective of this study was to examine the effect of the ConVR on the quality and quantity of consumer reports submitted directly to FAERS.","PeriodicalId":19812,"journal":{"name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","volume":"64 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82718466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Our aim was to review the efficacy, safety, and pharmacology of brexanolone (Zulresso), a new antidepressant with a novel mechanism of action, in the treatment of postpartum depression (PPD). Pertinent data and information were obtained via PubMed (1993 to August 2018). Articles published in English that evaluated the safety and efficacy of brexanolone and other off‐label PPD treatments were included. Literature regarding epidemiology and pathophysiology of PPD was also selected. Brexanolone, administered as an intravenous infusion over 60 hours, produced a statistically significant and clinically meaningful reduction in Hamilton Depression Rating Scale (HAM‐D) scores compared with placebo at both 60 and 90 μg/kg/hour in patients with moderate to severe PPD. Brexanolone groups had higher response and remission rates compared with placebo. Common adverse effects were somnolence, dizziness, and headache. A small percentage (4%) of patients required cessation of therapy due to excessive sedation or loss of consciousness. Although the evidence for brexanolone as a novel treatment for PPD looks promising, a Risk Evaluation and Mitigation Strategies (REMS) program requirement and the logistics of prolonged infusions serve as barriers to treatment. A discussion of these obstacles as well as pharmacokinetics, monitoring, and dosing is provided. Brexanolone is a novel antidepressant indicated for the treatment of PPD. Clinical trials demonstrated that brexanolone significantly reduces depression scores in women with moderate to severe PPD. Due to risk of oversedation and loss of consciousness, a REMS program will be put in place to mitigate the risk of adverse events.
{"title":"Brexanolone for Postpartum Depression: Clinical Evidence and Practical Considerations","authors":"Lauren D Leader, M. O'connell, A. Vandenberg","doi":"10.1002/phar.2331","DOIUrl":"https://doi.org/10.1002/phar.2331","url":null,"abstract":"Our aim was to review the efficacy, safety, and pharmacology of brexanolone (Zulresso), a new antidepressant with a novel mechanism of action, in the treatment of postpartum depression (PPD). Pertinent data and information were obtained via PubMed (1993 to August 2018). Articles published in English that evaluated the safety and efficacy of brexanolone and other off‐label PPD treatments were included. Literature regarding epidemiology and pathophysiology of PPD was also selected. Brexanolone, administered as an intravenous infusion over 60 hours, produced a statistically significant and clinically meaningful reduction in Hamilton Depression Rating Scale (HAM‐D) scores compared with placebo at both 60 and 90 μg/kg/hour in patients with moderate to severe PPD. Brexanolone groups had higher response and remission rates compared with placebo. Common adverse effects were somnolence, dizziness, and headache. A small percentage (4%) of patients required cessation of therapy due to excessive sedation or loss of consciousness. Although the evidence for brexanolone as a novel treatment for PPD looks promising, a Risk Evaluation and Mitigation Strategies (REMS) program requirement and the logistics of prolonged infusions serve as barriers to treatment. A discussion of these obstacles as well as pharmacokinetics, monitoring, and dosing is provided. Brexanolone is a novel antidepressant indicated for the treatment of PPD. Clinical trials demonstrated that brexanolone significantly reduces depression scores in women with moderate to severe PPD. Due to risk of oversedation and loss of consciousness, a REMS program will be put in place to mitigate the risk of adverse events.","PeriodicalId":19812,"journal":{"name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","volume":"47 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72669604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
C. Philpott, C. Droege, M. Droege, D. Healy, Joshua D. Courter, N. Ernst, N. Harger, M. Foertsch, J. Winter, Kristen E. Carter, Suzanne Van Fleet, K. Athota, E. Mueller
To evaluate extended‐infusion (EI) cefepime pharmacokinetics (PK) and pharmacodynamic target attainment in critically ill patients receiving continuous venovenous hemofiltration (CVVH) or continuous venovenous hemodialysis (CVVHD).
{"title":"Pharmacokinetics and Pharmacodynamics of Extended‐Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open‐Label Study","authors":"C. Philpott, C. Droege, M. Droege, D. Healy, Joshua D. Courter, N. Ernst, N. Harger, M. Foertsch, J. Winter, Kristen E. Carter, Suzanne Van Fleet, K. Athota, E. Mueller","doi":"10.1002/phar.2332","DOIUrl":"https://doi.org/10.1002/phar.2332","url":null,"abstract":"To evaluate extended‐infusion (EI) cefepime pharmacokinetics (PK) and pharmacodynamic target attainment in critically ill patients receiving continuous venovenous hemofiltration (CVVH) or continuous venovenous hemodialysis (CVVHD).","PeriodicalId":19812,"journal":{"name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76416735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bartlett et al. reported in a large US-based single-center study that the tacrolimus metabolism rate, defined as the concentration-to-dose ratio (CDR), does not have an impact on biopsy-proven acute rejection as previously shown in kidney transplant recipients. In contrast to our results, they observed a higher mortality rate in nonrapid metabolizers (NRM) compared to rapid metabolizers (RM). Although estimated glomerular filtration rate values were lower at several time points in RMs compared to NRM, they vote against CDR-based tailoring of the tacrolimus therapy. First, Bartlett et al. defined RM and NRM differently compared to previous studies. Their CDR cut-off for RM/NRM was 2.04 (ng/ml)*1/ mg that is considerably higher compared to previous definitions [< 1.05 (ng/ml)*1/mg] 4 and < 0.67 (ng/ml)*1/mg. In accordance, they identified 74.3% RM compared to 39.1% and 25.2% RM. Hence, a substantial number of their RM would have been classified as NRM in the other studies. Notably, as kidney transplant recipients with a CDR between 1.05 and 1.54 (ng/ml)*1/ mg (intermediate group) showed comparable results to patients with a CDR ≥ 1.55 (ng/ml)*1/ mg we have even chosen to combine both groups in later analyses. Second, in contrast to European studies, Bartlett et al.’s study included 40% African Americans; ethnicity has a known impact. 7 Third, the low rejection rate (e.g., in contrast to Egeland et al.), might have masked differences as already stated by the authors. Different induction therapies and missing protocol biopsies, frequently detecting rejection in stable grafts, might be responsible. 8 Fourth, Bartlett et al. use a lower tacrolimus trough level compared with our data. 4 Lower troughs might mitigate tacrolimus adverse effects. 9 Fifth, the authors speculate that NRM have a higher exposure to tacrolimus over time, leading to increased toxicity, which is not supported by data. In fact, others showed comparable area under the receiver operating characteristic curve between RM and NRM. 11 A reanalysis of the study data using different CDR cut-offs would be interesting.
{"title":"Alternative Viewpoint on Tacrolimus Concentration‐to‐Dose Ratios in Kidney Transplant Recipients and Relationship to Clinical Outcomes","authors":"G. Thölking, S. Reuter","doi":"10.1002/phar.2321","DOIUrl":"https://doi.org/10.1002/phar.2321","url":null,"abstract":"Bartlett et al. reported in a large US-based single-center study that the tacrolimus metabolism rate, defined as the concentration-to-dose ratio (CDR), does not have an impact on biopsy-proven acute rejection as previously shown in kidney transplant recipients. In contrast to our results, they observed a higher mortality rate in nonrapid metabolizers (NRM) compared to rapid metabolizers (RM). Although estimated glomerular filtration rate values were lower at several time points in RMs compared to NRM, they vote against CDR-based tailoring of the tacrolimus therapy. First, Bartlett et al. defined RM and NRM differently compared to previous studies. Their CDR cut-off for RM/NRM was 2.04 (ng/ml)*1/ mg that is considerably higher compared to previous definitions [< 1.05 (ng/ml)*1/mg] 4 and < 0.67 (ng/ml)*1/mg. In accordance, they identified 74.3% RM compared to 39.1% and 25.2% RM. Hence, a substantial number of their RM would have been classified as NRM in the other studies. Notably, as kidney transplant recipients with a CDR between 1.05 and 1.54 (ng/ml)*1/ mg (intermediate group) showed comparable results to patients with a CDR ≥ 1.55 (ng/ml)*1/ mg we have even chosen to combine both groups in later analyses. Second, in contrast to European studies, Bartlett et al.’s study included 40% African Americans; ethnicity has a known impact. 7 Third, the low rejection rate (e.g., in contrast to Egeland et al.), might have masked differences as already stated by the authors. Different induction therapies and missing protocol biopsies, frequently detecting rejection in stable grafts, might be responsible. 8 Fourth, Bartlett et al. use a lower tacrolimus trough level compared with our data. 4 Lower troughs might mitigate tacrolimus adverse effects. 9 Fifth, the authors speculate that NRM have a higher exposure to tacrolimus over time, leading to increased toxicity, which is not supported by data. In fact, others showed comparable area under the receiver operating characteristic curve between RM and NRM. 11 A reanalysis of the study data using different CDR cut-offs would be interesting.","PeriodicalId":19812,"journal":{"name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","volume":"153 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79628527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chintan V. Dave, A. Goodin, Yanmin Zhu, A. Winterstein, Xi Wang, Adel A. Alrwisan, A. Hartzema
Despite the rising incidence of neonatal abstinence syndrome (NAS), data evaluating trends in maternal risk factors associated with NAS have not been available for recent years, a period characterized by declining opioid prescriptions. The objective of this study was to examine the prevalence of opioid‐ and non–opioid‐related factors associated with NAS, and by mutually exclusive subgroups of deliveries without prescription‐opioid use, with prescription‐opioid use, and with opioid‐use disorder (OUD).
{"title":"Prevalence of Maternal‐Risk Factors Related to Neonatal Abstinence Syndrome in a Commercial Claims Database: 2011‐2015","authors":"Chintan V. Dave, A. Goodin, Yanmin Zhu, A. Winterstein, Xi Wang, Adel A. Alrwisan, A. Hartzema","doi":"10.1002/phar.2315","DOIUrl":"https://doi.org/10.1002/phar.2315","url":null,"abstract":"Despite the rising incidence of neonatal abstinence syndrome (NAS), data evaluating trends in maternal risk factors associated with NAS have not been available for recent years, a period characterized by declining opioid prescriptions. The objective of this study was to examine the prevalence of opioid‐ and non–opioid‐related factors associated with NAS, and by mutually exclusive subgroups of deliveries without prescription‐opioid use, with prescription‐opioid use, and with opioid‐use disorder (OUD).","PeriodicalId":19812,"journal":{"name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","volume":"104 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80538415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"On the 40th Anniversary of the American College of Clinical Pharmacy: Musing About Books, Journals, and Libraries","authors":"C. DeVane","doi":"10.1002/phar.2327","DOIUrl":"https://doi.org/10.1002/phar.2327","url":null,"abstract":"","PeriodicalId":19812,"journal":{"name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","volume":"13 2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89665754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：